A Study of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms Involving the Visceral Branch Vessels

Overview

Información sobre este estudio

The purpose of this study is to assess the initial feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) in the treatment of aortic aneurysms involving the visceral branch vessels.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria

  • Aortic aneurysm involving the visceral vessels requiring treatment
  • Adequate access for TAMBE Device components
  • Appropriate aortic anatomy to receive the TAMBE Device
  • Age ≥ 18 years at the time of informed consent signature
  • Male or infertile female
  • The patient is considered high risk for open repair as deemed by the treating physician
  • Capable of complying with protocol requirements, including follow-up
  • An Informed Consent Form signed by Subject or legal representative 
  • Additional inclusion criteria may apply

Exclusion Criteria

  • Prior aortic surgery
  • Ruptured or leaking aortic aneurysm
  • Aneurysmal dilatation due to chronic aortic dissection
  • Infected aorta
  • Mycotic aneurysm
  • Life expectancy <2 years
  • Myocardial infarction or stroke within 6 weeks of treatment
  • Systemic infection which may increase risk of endovascular graft infection
  • Degenerative connective tissue disease, e.g. Marfan's or Ehler-Danlos Syndrome
  • Participation in another drug or medical device study within 1 year of study enrollment
  • History of drug abuse, e.g. cocaine or amphetamine or alcohol, within 1 year of treatment
  • Tortuous or stenotic iliac and / or femoral arteries and the inability to use a conduit for vascular access
  • Known sensitivities or allergies to the device materials
  • Previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or known hypersensitivity to heparin
  • Body habitus or other medical condition which prevents adequate fluoroscopic and CT visualization of the aorta
  • Renal Insufficiency 
  • Additional exclusion criteria may apply

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Bernardo Mendes, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20201828

Mayo Clinic Footer